MMP-9 and the perioperative management of LASIK surgery

Current Opinion in Ophthalmology

Volumn 22, Issue 4, 2011, Pages 294-303

  Sambursky, Robert ^a,d   OBrien, Terrence P ^b,c  

^a Manatee Sarasota Eye Clinic   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

dry eyes; dysfunctional tear syndrome; keratoconjunctivitis; laser in situ keratomileusis; metalloproteinase 9; MMP 9

Indexed keywords

AZITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN; DOXYCYCLINE; GELATINASE B; METHYLPREDNISOLONE; STEROID;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATARACT; CORNEA EPITHELIUM; DRY EYE; GLAUCOMA; HUMAN; HYPEROSMOLARITY; KERATOMILEUSIS; LASER EPITHELIAL KERATOMILEUSIS; NONHUMAN; PERIOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; TEAR FILM; UNSPECIFIED SIDE EFFECT;

DRY EYE SYNDROMES; HUMANS; KERATOCONJUNCTIVITIS; KERATOMILEUSIS, LASER IN SITU; MATRIX METALLOPROTEINASE 9; OSMOLAR CONCENTRATION; PERIOPERATIVE CARE; TEARS;

EID: 79959238645     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32834787bb     Document Type: Article

References (147)

1. Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006; 25:900-907. (Pubitemid 44763848)
2. McCollum C, Foulks G, Bodner B, et al. Rapid assay of lactoferrin in keratoconjunctivitis sicca. Cornea 1994; 13:505-508. (Pubitemid 24332725)
3. Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögrens syndrome keratoconjunctivitis sicca. Curr Eye Res 1999; 19:201-211. (Pubitemid 29500267)
4. Solomon A, Dursun D, Liu Z, et al. Pro-and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001; 42:2283-2292. (Pubitemid 32848857)
5. Afonso A, Sobrin L, Monroy DC, et al. Tear fluid gelatinase B activity correlates with IL-1a concentration and fluorescein tear clearance. Invest Ophthalmol Vis Sci 1999; 40:2506-2512. (Pubitemid 29455477)
6. Brignole F, Pisella PJ, Goldschild M, et al. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci 2000; 41:1356-1363. (Pubitemid 30261857)
7. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004; 137:337-342. (Pubitemid 38221009)
8. Ollivier F, Gilger B, Barrie K, et al. Proteinases of the cornea and preocular tear film. Vet Ophthalmol 2007; 10:199-206. (Pubitemid 46906338)
9. Sakamoto S, Sakamoto M. Degradative processes of connective tissue proteins with special emphasis on collagenolysis and bone reabsorption. Mol Aspects Med 1988; 10:301-428.
10. Woessner JF. Metalloproteinase and their inhibitors in connective tissue remodeling. FASEB J 1991; 5:2145-2154.
11. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6:121-125.
12. Corrales RM, Stern ME, De Paiva CS, et al. Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. Invest Ophthalmol Vis Sci 2006; 47:3293-3302. (Pubitemid 351639689)
13. Matrisian LM, Bowden GT, Krieg P, et al. The mRNA coding for the secreted transin is expressed more abundantly in malignant than in benign tumors. Proc Natl Acad Sci U S A 1986; 83:9413-9417. (Pubitemid 17223371)
14. Dean DD, Martel-Pelletier J, Pelletier JL, et al. Evidence for metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989; 84:678-685. (Pubitemid 19197004)
15. Liotta LA, Steeg PS, Stetler-StevensonWG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.Cell 1991; 64:327-336. (Pubitemid 121001258)
16. Fini ME, Girard MT. Expression of collagenolytic/gelatinolytic metalloproteinases by normal cornea. Invest Ophthalmol Vis Sci 1990; 31:1779-1788. (Pubitemid 20350902)
17. Li DQ, Shang TY, Kim H, et al. Regulated expression of collagenases MMP-1, -8, and -13 and stromelysins MMP-3, -10, and -11 by human corneal epithelial cells. Invest Ophthalmol Vis Sci 2003; 44:2928-2935.
18. Kjeldsen L, Sengelov H, Lollike K, et al. Isolation and characterization of gelatinase granules. Blood 1994; 83:1640-1649.
19. Matsubara M, Zieske JD, Fini ME. Mechanism of basement membrane dissolution preceding corneal ulceration. Invest Ophthalmol Vis Sci 1991; 32:3221-3237.
20. Fini ME, Parks WC, Rinehart WB, et al. Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury. Am J Pathol 1996; 149:1287-1301.
21. Ottino P, Taheri F, Bazen HE. Platelet-activating factor induces the gene expression of TIMP-1, -2, and PAI-1: imbalance between the gene expression of MMP-9 andmTIMP-1 and -2. Exp Eye Res 2002; 74:393-402. (Pubitemid 34948385)
22. Fukuda K, Fujitsu Y, Kumagai N, et al. Inhibition of matrix metalloproteinase-3 in human conjunctival fibroblasts by interleukin-4 or interleukin-13. Invest Ophthalmol Vis Sci 2006; 47:2857-2864. (Pubitemid 351639758)
23. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci 2004; 45:4293-4301. (Pubitemid 39564653)
24. Pflugfelder SC, de Paiva CS, Tong L, et al. Stress-activated protein kinases signaling pathways in dry eye and ocular surface disease. Ocul Surf 2005; 3:S154-S157.
25. Rosenbaum JT, Plank ST, Huang XN, et al. Detection of mRNA for the cytokines, interleukin-1a and interleukin-8, in corneas from patients with pseudophakic bullous keratopathy. Invest Ophthalmol Vis Sci 1995; 36:2151-2155.
26. Fabre EJ, Bureau J, Pouliquen Y, et al. Binding sites for human interleukin 1a, gamma interferon and tumor necrosis factor on cultured fibroblasts of normal corneas and keratoconus. Curr Eye Res 1991; 10:585-592.
27. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 15:2095-2147. (Pubitemid 26086851)
28. Bond M, Fabunmi RP, Baker AH, et al. Synergistic upregulation of metalloproteinase- by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998; 435:29-34. (Pubitemid 28432009)
29. Girard MT, Matsubara M, Fini ME. Transforming growth factor-beta and interleukin-1 modulate metalloproteinase expression by corneal stromal cells. Invest Ophthalmol Vis Sci 1991; 32:2441-2454.
30. Barton K, Monroy DC, Nava A, et al. Inflammatory cytokines in the tears of patients with ocular rosacea. Ophthalmology 1997; 104:1868-1874. (Pubitemid 28100344)
31. Matsumoto K, Ikema K, Tanihara H. Role of cytokines in pseudomonal keratitis. Cornea 2005; 24:43-49.
32. Cayphas S, Van Damme J, Vink A, et al. Identification of an interleukin HPI-like plasmacytoma growth factor produced by L cells in response to viral infection. J Immunol 1987; 139:2965-2969. (Pubitemid 17157465)
33. Girolomo ND, Kumar RK, Coroneo MT, et al. UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Invest Ophthalmol Vis Sci 2002; 43:3430-3437. (Pubitemid 35334350)
34. Ray A, Tatter SB, Santhanam DC, et al. Regulation of expression of interleukin-6: molecular and clinic studies. Ann N Y Acad Sci 1989; 557:353-362. (Pubitemid 19210840)
35. Black RA, Kronheim SR, Sleath PR. Activation of interleukin-1b by a coinduced protease. FEBS Lett 1989; 247:386-390.
36. Schonbeck V, Mach F, Libby P. Generation of biologically active IL-1b by matrix metalloproteinase a novel caspase-1 independent pathway of IL-1b processing. J Immunol 1998; 161:3340-3346.
37. Lemp MA. Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes. CLAO J 1995; 21:221-232.
38. Dogru M, Stern ME, Smith JA, et al. Changing trends in the definition and diagnosis of dry eyes. Am J Ophthalmol 2005; 140:507-508.
39. Brewitt H, Sistani F. Dry eye disease: the scale of the problem. Surv Ophthalmol 2001; 45:S199-S202.
40. Schaumberg DA, Buring JE, Sullivan DA, et al. Hormone replacement therapy and dry eye syndrome. JAMA 2001; 286:2114-2119. (Pubitemid 34041596)
41. Albietz JM. Dry eye: an update on clinical diagnosis, management and promising new treatments. Clin Exp Optom 2001; 84:4-18. (Pubitemid 33274911)
42. Albietz JM. Conjunctival histological findings of dry eye and nondry eye contact lens wearing subjects. CLAO J 2001; 27:35-40. (Pubitemid 32111036)
43. Hovanesian JA, Shah SS, Maloney RK. Symptoms of dry eye and recurrent erosion syndrome after refractive surgery. J Cataract Refract Surg 2001; 27:577-584.
44. Altintas O, Caglar Y, Yuksel N, et al. The effects of menopause and hormone replacement therapy on quality and quantity of tear, intraocular pressure and ocular blood flow. Ophthalmologica 2004; 218:120-129. (Pubitemid 38344103)
45. Toda I. LASIK and dry eye. Compr Ophthalmol Update 2007; 8:79-85. (Pubitemid 46910148)
46. Wilson SE, Stulting RD. Agreement of physician treatment practices with the International Task Force guidelines for diagnosis and treatment of dry eye disease. Cornea 2007; 26:284-289. (Pubitemid 46568827)
47. Vitale S, Goodman LA, Reed GF, et al. Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögrens syndrome-related dry eye. Health Qual Life Outcomes 2004; 2:44.
48. Schiffman RM, Walt JG, Jacobsen F, et al. Utility assessment among patients with dry eye disease. Ophthalmology 2003; 110:1412-1419. (Pubitemid 36842481)
49. Nettune GR, Pflugfelder SC. Post-LASIK tear dysfunction and dysesthesia. Ocul Surf 2010; 8:135-145.
50. Massingale ML, Li X, Vallabhajosyula M, et al. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 2009; 28:1023-1027.
51. Yeh S, Song XJ, Farley W, et al. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest Ophthalmol Vis Sci 2003; 44:124-129. (Pubitemid 36134264)
52. Acera A, Rocha G, Vecino E, et al. Inflammatory markers in the tears of patients with ocular surface disease. Ophthalmic Res 2008; 40:315-321.
53. Sobrin L, Liu Z, Monroy DC, et al. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci 2000; 41:1703-1709. (Pubitemid 30354340)
54. Pflugfelder SC, Farley W, Luo L, et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am J Pathol 2005; 166:61-71. (Pubitemid 40051660)
55. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21:7724-7732. (Pubitemid 32904971)
56. Sternlicht M, Werb Z. How matrix metalloproteinases regulate cell behavior. Ann Rev Cell Dev Biol 2001; 17:463-516. (Pubitemid 33096184)
57. Behzadian M, Wang X, Ghaly J, et al. TGF-beta increases retinal endothelial cell permeability by increasing MMP-9: possible role of glial cells in endothelial barrier function. Invest Ophthalmol Vis Sci 2001; 42:853-859. (Pubitemid 32206931)
58. Brignole F, De Saint-Jean M, Goldschild M, et al. Expression of Fas-Fas ligand antigens and apoptotic marker APO 2.7 by the human conjunctival epithelium: positive correlation with class II HLA-DR expression in inflammatory ocular surface disorders. Exp Eye Res 1998; 67:687-697. (Pubitemid 29052405)
59. Solomon R, Donnenfeld ED, Perry HD. The effects of LASIK on the ocular surface. Ocul Surf 2004; 2:34-44. (Pubitemid 41263886)
60. Bode W, Fernandez-Catalan C, Tschesche H, et al. Structural properties of matrix metalloproteinases. Cell Mol Life Sci 1999; 55:639-652. (Pubitemid 29221596)
61. Vincenti MP. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes: transcriptional and posttranscriptional regulation, signal transduction and cell-type specific expression. Methods Mol Biol 2001; 151:121-148.
62. Ye HQ, Maeda M, Yu FS, et al. Differential expression of MT1-MMP (MMP-14) and collagenase III (MMP-13) genes in normal and wounded rat corneas. Invest Ophthalmol Vis Sci 2000; 41:2894-2899.
63. Ye HQ, Azar DT. Expression of gelatinases A and B, and TIMPs 1 and 2 during corneal wound healing. Invest Ophthalmol Vis Sci 1998; 39:913-921. (Pubitemid 28196677)
64. Luo L, Li DQ, Corrales RM, et al. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens 2005; 31:186-193. (Pubitemid 43197004)
65. Li DQ, Chen Z, Song XJ, et al. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2004; 45:4302-4311. (Pubitemid 39564654)
66. Smith VA, Rishmawi H, Hussein H, et al. Tear film MMP accumulation and corneal disease. Br J Ophthalmol 2001; 85:147-153. (Pubitemid 32146751)
67. Chotikavanich S, de Paiva CS, Li de Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci 2009; 50:3203-3209.
68. Leonardi A, Brun P, Abatangelo G, et al. Tear levels and activity of matrix metalloproteinase MMP-1 and MMP-9 in vernal keratoconjunctivitis. Invest Ophthalmol Vis Sci 2003; 44:3052-3058. (Pubitemid 36759772)
69. Lema I, Sobrino T, Durán JA, et al. Subclinical keratoconus and inflammatory molecules from tears. Br J Ophthalmol 2009; 93:820-824.
70. Honda N, Miyai T, Nejima R, et al. Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface. Arch Ophthalmol 2010; 128:466-471.
71. Fini M, Cook J, Mohan R. Proteolytic mechanisms in corneal ulceration and repair. Arch Dermatol Res 1998; 290:S12-S23.
72. Jenkins MS, Brown SI, Lempert SL, et al. Ocular rosacea. Am J Ophthalmol 1979; 88:618-622. (Pubitemid 9231716)
73. Akpek EK, Merchard A, Pinar V, et al. Ocular rosacea: patient characteristics and follow-up. Ophthalmology 1997; 104:1863-1867. (Pubitemid 28100343)
74. Bron AJ. Diagnosis of dry eye. Surv Ophthalmol 2001; 45:S221-S226.
75. Goto E, Tseng SC. Differentiation of lipid tear deficiency dry eye by kinetic analysis of tear interference images. Arch Ophthalmol 2003; 121:173-180. (Pubitemid 36184029)
76. Goto E, Dogru M, Kojima T, et al. Computer-synthesis of an interference color chart of human tear lipid layer, by a colorimetric approach. Invest Ophthalmol Vis Sci 2003; 44:4693-4697. (Pubitemid 37315280)
77. Wilson SE. Laser in situ keratomileusis-induced (presumed) neurotrophic epitheliopathy. Ophthalmology 2001; 108:1082-1087. (Pubitemid 32500025)
78. Goto T, Zheng X, Okamoto S, et al. Tear film stability analysis system: introducing a new application for videokeratography. Cornea 2004; 23:S65-S70. (Pubitemid 39458547)
79. Montes-Mico R, Alio JL, Charman WN. Dynamic changes in the tear film in dry eyes. Invest Ophthalmol Vis Sci 2005; 46:1615-1619. (Pubitemid 44843594)
80. Tomlinson A, Khanal S, Ramaesh K, et al. Tear film osmolarity: determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci 2006; 47:4309-4315. (Pubitemid 46579353)
81. Khanal S, Tomlinson A, McFadyen A, et al. Dry eye diagnosis. Invest Ophthalmol Vis Sci 2008; 49:1407-1414.
82. RPS InflammaDry Detector Package Insert. Spec 375 Rev 0. 2010.
83. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 2002; 120:330-337. (Pubitemid 34250055)
84. Peyman GA, Sanders DR, Batlle JF, et al. Cyclosporine 0.05% ophthalmic preparation to aid recovery from loss of corneal sensitivity after LASIK. J Refract Surg 2008; 24:337-343. (Pubitemid 351543998)
85. De Paiva CS, Chen Z, Koch DD, et al. The incidence and risk factors for developing dry eye after myopic LASIK. Am J Ophthalmol 2006; 141:438-445. (Pubitemid 43265946)
86. Shoja MR, Besharati MR. Dry eye after LASIK for myopia: incidence and risk factors. Eur J Ophthalmol 2007; 17:1-6. (Pubitemid 46580592)
87. Duffey RJ, Leaming D. US trends in refractive surgery: 2004 ISRS/AAO survey. J Refract Surg 2005; 21:742-748. (Pubitemid 41705626)
88. Toda I. LASIK and the ocular surface. Cornea 2008; 27 (Suppl1):S70-S76.
89. Bailey MD, Mitchell GL, Dhaliwal DK, et al. Reasons patients recommend laser in situ keratomileusis. J Cataract Refract Surg 2004; 30:1861-1866. (Pubitemid 39165914)
90. Jabbur NS, Sakatani K, OBrien TP. Survey of complications and recommendations for management in dissatisfied patients seeking a consultation after refractive surgery. J Cataract Refract Surg 2004; 30:1867-1874. (Pubitemid 39165915)
91. Berry S, Mangione CM, Lindblad AS, et al. Development of the national eye institute refractive error correction quality of life questionnaire: focus groups. Ophthalmology 2003; 110:2285-2291. (Pubitemid 37485156)
92. Ambrosio R. LASIK-associated Dry Eye and Neurotrophic Epitheliopathy: Pathophysiology and Strategies for Prevention and Treatment. J Refract Surg 2008; 24:396-407.
93. Toda I, Asano-Kato N, Komai-Hori Y, et al. Dry eye after laser in situ keratomileusis. Am J Ophthalmol 2001; 132:1-7. (Pubitemid 32600882)
94. Lee JB, Ryu CH, Kim J, et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. J Cataract Refract Surg 2000; 26:1326-1331.
95. Yu EY, Leung A, Rao S, Lam DS. Effects of laser in situ keratomileusis on tear stability. Ophthalmology 2000; 107:2131-2135.
96. Battat L,Macri A, Dursun D, et al. Effects of laser in situ keratomileusis on tear production, clearance, and the ocular surface. Ophthalmology 2001; 108:1230-1235. (Pubitemid 32568132)
97. Benitez-del-Castillo JM, del Rio T, Iradier T, et al. Decrease in tear secretion and corneal sensitivity after laser in situ keratomileusis. Cornea 2001; 20:30-32. (Pubitemid 32038151)
98. Patel S, Perez-Santonja JJ, Alio JL, et al. Corneal sensitivity and some properties of the tear film after laser in situ keratomileusis. J Refract Surg 2001; 17:17-24. (Pubitemid 32101884)
99. Albietz JM, Lenton LM, McLennan SG. Effect of laser in situ keratomileusis for hyperopia on tear film and ocular surface. J Refract Surg 2002; 18:113-123. (Pubitemid 34727800)
100. Albietz JM, Lenton LM. Management of the ocular surface and tear film before, during, and after laser in situ keratomileusis. J Refract Surg 2004; 20:62-71. (Pubitemid 38101585)
101. Albietz JM, Lenton LM, McLennan SG. Chronic dry eye and regression after laser in situ keratomileusis for myopia. J Cataract Refract Surg 2004; 30:675-684. (Pubitemid 38429645)
102. Ozdamar A, Aras C, Karakas N, et al. Changes in tear flow and tear film stability after photorefractive keratectomy. Cornea 1999; 18:437-439. (Pubitemid 29294067)
103. Toda I, Asano-Kato N, Hori-Komai Y, et al. Laser-assisted in situ keratomileusis for patients with dry eye. Arch Ophthalmol 2002; 120:1024-1028. (Pubitemid 34856069)
104. Alio JL, Artola A, Belda JI, et al. LASIK in patients with rheumatic diseases: a pilot study. Ophthalmology 2005; 112:1948-1954. (Pubitemid 41551923)
105. Toda I, Asano-Kato N, Hori-Komai Y, et al. Ocular surface treatment before laser in situ keratomileusis in patients with severe dry eye. J Refract Surg 2004; 20:270-275. (Pubitemid 38657019)
106. Patel SV, McLaren JW, Hodge DO, Bourne WM. Confocal microscopy in vivo in corneas of long-term contact lens wearers. Invest Ophthalmol Vis Sci 2002; 43:995-1003. (Pubitemid 34258266)
107. Konomi K, Chen LL, Tarko RS, et al. Preoperative characteristics and a potential mechanism of chronic dry eye after LASIK. Invest Ophthalmol Vis Sci 2008; 49:168-174.
108. Tuisku IS, Lindbohm N, Wilson SE, et al. Dry eye and corneal sensitivity after high myopic LASIK. J Refract Surg 2007; 23:338-342. (Pubitemid 46608844)
109. Albietz JM, Lenton LM, McLennan SG. Dry eye after LASIK: comparison of outcomes for Asian and Caucasian eyes. Clin Exp Optom 2005; 88:89-96.
110. Wilson SE, Ambrosio R. Laser in situ keratomileusis-induced neurotrophic epitheliopathy. Am J Ophthalmol 2001; 132:405-406. (Pubitemid 32768612)
111. Linna TU, Vesaluoma MH, Perez-Santonja JJ, et al. Effect of myopic LASIK on corneal sensitivity and morphology of subbasal nerves. Invest Ophthalmol Vis Sci 2000; 41:393-397. (Pubitemid 30080440)
112. Vroman DT, Sandoval HP, Fernandez de Castro LE, et al. Effect of hinge location on corneal sensation and dry eye after laser in situ keratomileusis for myopia. J Cataract Refract Surg 2005; 31:1881-1887. (Pubitemid 41773157)
113. Michaeli A, Slomovic AR, Sakhichand K, et al. Effect of laser in situ keratomileusis on tear secretion and corneal sensitivity. J Refract Surg 2004; 20:379-383. (Pubitemid 38971031)
114. Savini G, Barboni P, Zanini M, et al. Ocular surface changes in laser in situ keratomileusis-induced neurotrophic epitheliopathy. J Refract Surg 2004; 20:803-809. (Pubitemid 39546369)
115. Perez-Santonja JJ, Sakla HF, Cardona C, et al. Corneal sensitivity after photorefractive keratectomy and laser in situ keratomileusis for low myopia. Am J Ophthalmol 1999; 127:497-504. (Pubitemid 29215758)
116. Nassaralla BA, McLeod SD, Nasaralla JJ Jr. Effect of myopic LASIK on human corneal sensitivity. Ophthalmology 2003; 110:497-502. (Pubitemid 36262731)
117. Kim WS, Kim JS. Changes in corneal sensitivity following laser in situ keratomileusis. J Cataract Refract Surg 1999; 25:368-373.
118. Donnenfeld ED, Solomon K, Perry HD, et al. The effect of hinge position on corneal sensation and dry eye after LASIK. Ophthalmology 2003; 110:1023-1029. (Pubitemid 36560506)
119. Mian SI, Shtein RM, Nelson A, et al. Effect of hinge position on corneal sensation and dry eye after laser in situ keratomileusis using a femtosecond laser. J Cataract Refract Surg 2007; 33:1190-1194. (Pubitemid 46951011)
120. Kumano Y, Matsui H, Zushi I, et al. Recovery of corneal sensation after myopic correction by laser in situ keratomileusis with a nasal or superior hinge. J Cataract Refract Surg 2003; 29:757-761. (Pubitemid 36418017)
121. Shin SY, Lee YJ. Conjunctival changes induced by LASIK suction ring in a rabbit model. Ophthalmic Res 2006; 38:343-349.
122. Rodriguez-Prats JL, Hamdi IM, Rodriguez AE, et al. Effect of suction ring application during LASIK on goblet cell density. J Refract Surg 2007; 23:559-562. (Pubitemid 46932376)
123. Barequet IS, Hirsh A, Levinger S. Effect of thin femtosecond LASIK flaps on corneal sensitivity and tear function. J Refr Surg 2008; 24:897-902.
124. Donnenfeld ED, Ehrenhaus M, Solomon R, et al. Effect of hinge width on corneal sensation and dry eye after laser in situ keratomileusis. J Cataract Refract Surg 2004; 30:790-797. (Pubitemid 38501472)
125. Mutoh T, Nishio M, Matsumoto Y, et al. Correlation between the matrix metalloproteinase-9 activity and chondroitin sulfate concentrations in tear fluid after laser in situ keratomileusis. Clin Ophthalmol 2010; 4:823-828.
126. Nowroozzadeh MH. Early flap dislocation with perioperative brimonidine use in laser in situ keratomileusis. J Cataract Refract Surg 2010; 36:368.
127. Oh-i K, Mori H, Kubo M, et al. LASIK flap dislocation by blunt trauma seven weeks after surgery. J Refract Surg 2005; 21:93-94. (Pubitemid 40144432)
128. Esquenazi S, Esquenazi I, Grunstein L, et al. Immunohistological evaluation of the healing response at the flap interface in patients with LASIK ectasia requiring penetrating keratoplasty. J Refract Surg 2009; 25:739-746.
129. Mullholland B. Matrix metalloproteinase distribution during early corneal wound healing. Eye 2005; 19:584-588.
130. Azar DT, Pluznik D, Jain S, et al. Gelatinase B and A expression after laser in situ keratomileusis and photorefractive keratectomy. Arch Ophthalmol 1998; 116:1206-1208. (Pubitemid 29106442)
131. Fournié PR, Gordon GM, Dawson DG, et al. Correlation between epithelial ingrowth and basement membrane remodeling in human corneas after laser-assisted in situ keratomileusis. Arch Ophthalmol 2010; 128:426-436.
132. Schallhorn SC, Amesbury EC, Tanzer DJ. Avoidance, recognition, and management of LASIK complications. Am J Ophthalmol 2006; 141:733-739.
133. Li DQ, Luo L, Chen Z, et al. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res 2006; 82:588-596. (Pubitemid 43122089)
134. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögrens syndrome. Ophthalmology 1999; 106:811-816. (Pubitemid 30194327)
135. Sall K, Stevenson OD, Mundorf TK, et al. CSA phase 3 study group: two multicenter, randomized studies of the efficacy and safety of cyclosporin ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000; 107:631-639. (Pubitemid 30191329)
136. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006; 25:171-175. (Pubitemid 43362715)
137. Pflugfelder SC. Anti-inflammatory therapy of dry eye. Ocul Surf 2003; 1:31-36. (Pubitemid 41263855)
138. Foulks GN. Topical cyclosporine for treatment of ocular surface disease. Int Ophthalmol Clin 2006; 46:105-122. (Pubitemid 44632214)
139. Gürdal C, Genc I, Sarac O, et al. Topical cyclosporine in thyroid orbitopathyrelated dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-
140. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporine an ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000; 107:967-974.
141. Avunduk AM, Avunduk MC, Varnell ED, et al. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 2003; 136:593-602. (Pubitemid 37153173)
142. Pflugfelder SC, de Paiva CS, Villareal AL, et al. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea 2008; 27:64-69.
143. De Paiva CS, Corrales RM, Villarreal AL, et al. Anti-inflammatory therapy preserves corneal barrier function in experimental murine dry eye. Invest Ophthalmol Vis Sci 2005; 46:E-Abstract 2423.
144. Djalilian AR, Nagineni CN, Mahesh SP, et al. Inhibition of inflammatory cytokine production in human corneal cells by dexamethasone, but not cyclosporin. Cornea 2006; 25:709-714. (Pubitemid 44671862)
145. Seedor JA, Perry HD, McNamara TF, et al. Systemic tetracycline treatment of alkali-induced corneal ulceration in rabbits. Arch Ophthalmol 1987; 105:268-271. (Pubitemid 17013713)
146. SternME, Pflugfelder SC. Inflammation in dry eye. Ocul Surf 2004; 2:124-130. (Pubitemid 41263879)
147. Perry HD, Donnenfeld ED. Topical 0.05% cyclosporine in the treatment of dry eye. Expert Opin Pharmacother 2004; 5:2099-2107. (Pubitemid 39406112)